Table 3 Univariate and multivariate analysis of prognostic factors for cancer-specific survival of metastatic RCC patients treated by nivolumab monotherapy.

From: Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma

 

Univariate analysis

Multivariate analysis

HR

95% CI

P

HR

95% CI

P

Age (<66 vs. ≥66 years)

1.33

0.36–4.99

0.670

   

Gender (Male vs. Female)

1.98

0.49–8.07

0.341

   

WHO/ISUP grade (1, 2 vs. 3, 4)

13.9

1.64–117.4

0.016

22.49

1.44–350.4

0.026

Coagulative necrosis (absence vs. presence)

1.39

0.37–5.27

0.630

   

MSKCC risk classification

(Good/Intermediate vs. Poor)

14.8

2.97–73.66

0.001

21.14

2.41–185.2

0.006

Number of prior therapies (1 vs. ≥2)

0.52

0.14–1.98

0.338

   

NLR (<3.45 vs. ≥3.45)

3.05

0.75–12.36

0.119

   

PLR (<1.61 vs. ≥1.61)

1.88

0.47–7.52

0.374

   

CRP (<1 mg/dL vs. ≥1 mg/dL)

2.79

0.68–11.41

0.153

   
  1. Abbreviations: RCC = renal cell carcinoma, HR = hazard ratio, CI = confidence interval, MSKCC = Memorial Sloan Kettering Cancer Center, NLR = neutrophil to lymphocyte ratio, PLR = platelet to lymphocyte ratio, CRP = C reactive protein.
Back to article page